BlackSwan Pharma announced today exciting news concerning its development candidate CD-160130 resulting from its recent collaboration with Professor Annarosa Arcangeli of the Department of Experimental Pathology and Oncology at the University of Florence (Italy). These findings demonstrate for the first time that selective inhibition of hERG1 channel isoforms can be achieved and may represent an important milestone since the targeting of hERG1 in tumour cells can be seen as a means to both induce apoptosis and also to overcome the resistance to classical chemotherapeutic drugs used for the treatment of leukaemias.
